Overcoming Scalability Challenges With Autologous Therapies

Source: Catalent

Autologous immunotherapies have evolved in recent years to bring breakthrough treatments to the market. However, the complexity of the production process often results in extended timelines and high manufacturing costs, limiting the scalability and application across therapeutic indications. Therefore, cell therapy providers continue to make new investments to develop standardized and optimized scale-out strategies while balancing the customized processes for each patient treatment.

In this webinar, Catalent presents a clinical-to-commercial perspective on autologous therapies. Professor Gerhard Bauer discusses the current challenges associated with autologous therapies and Dr. James Crutchley speaks to the various solutions available for commercial scale-up of advanced therapeutics.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma